Tozorakimab (MEDI3506) met its primary and key secondary end points in the Phase 3 OBERON ( NCT05166889) and TITANIA ( ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results